Marta Celorrio Navarro

Medicine & Life Sciences

1. JZL 184 100%
2. Parkinson Disease 94%
3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 87%
4. Monoacylglycerol Lipases 83%
5. Traumatic Brain Injury 81%
6. Endocannabinoids 78%
7. Probenecid 68%
8. N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-pyridine-2-ylbenzamide 57%
9. 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol 54%
10. Brain Injuries 53%
11. Neuroglia 48%
12. Cannabinoid Receptor CB2 48%
13. Cannabinoid Receptor CB1 44%
14. Secondary Parkinson Disease 43%
15. Hypoxia 43%
16. fatty-acid amide hydrolase 41%
17. Neuroprotective Agents 39%
18. Dopamine D3 Receptors 39%
19. Globus Pallidus 37%
20. Mandibular Nerve 36%
21. Parvalbumins 35%
22. cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester 34%
23. Dysbiosis 34%
24. Minocycline 34%
25. 4-phenyl-1,2,3,6-tetrahydropyridine 34%
26. AMPA Receptors 32%
27. Facial Paralysis 32%
28. Animals 31%
29. Acetylcysteine 31%
30. Phenotype 30%
31. Glutamate Receptors 30%
32. Facial Nerve 30%
33. Cannabis 29%
34. Neurogenesis 29%
35. Brain 27%
36. Keratinocytes 26%
37. Neuroprotection 26%
38. Smoke 26%
39. Neuronal Plasticity 26%
40. Cannabidiol 26%
41. Cannabinoid Receptors 26%
42. Wounds and Injuries 23%
43. Dopamine 23%
44. Animal Models 23%
45. Dronabinol 22%
46. Microglia 22%
47. Cannabinoids 21%
48. Rehabilitation 21%
49. glyceryl 2-arachidonate 19%
50. Neurons 19%